Core Laboratories NV (NYSE:CLB) Earning Somewhat Favorable News Coverage, Report Shows

Xavier Trudeau
Août 13, 2017

Media coverage about Core Laboratories N.V. (NYSE:CLB) has been trending somewhat positive recently, according to Accern Sentiment. Ltd.'s holdings in Core Laboratories N.V. were worth $568,000 as of its most recent filing with the SEC.

Several other large investors also recently added to or reduced their stakes in CLB. Core Laboratories N.V.'s revenue was up 10.7% compared to the same quarter past year. BlackRock Inc. now owns 1,598,608 shares of the oil and gas company's stock valued at $184,672,000 after buying an additional 1,556,938 shares during the period. The value of the total investment in Core Laboratories N.V. went from $20,539,000 to $18,613,000 decreasing 9.4% quarter over quarter.

Shares of Core Laboratories N.V. The institutional investor bought 4,315 shares of the oil and gas company's stock, valued at approximately $437,000. Finally, First Bank & Trust boosted its position in Core Laboratories N.V.by 2.7% in the first quarter. Sei Investments Co. now owns 665,817 shares of the oil and gas company's stock valued at $67,426,000 after buying an additional 247,042 shares during the period. Advisory Services Network LLC acquired a new position in Core Laboratories N.V. during the first quarter valued at about $118,000. First Bank & Trust now owns 1,411 shares of the oil and gas company's stock valued at $163,000 after buying an additional 37 shares in the last quarter. The company has a market capitalization of $4.10 billion, a price-to-earnings ratio of 57.01 and a beta of 1.60. Company chares are trading at $92.92 which is quite a bit lower than $101.46, the stock's 50 day moving average and which is significantly below the 200 day moving average of $108.84.

Core Laboratories N.V. had a net margin of 11.80% and a return on equity of 49.29%. (NYSE:CLB) last posted its quarterly earnings results on Monday, July 24th. The oil and gas company reported $0.52 EPS for the quarter, beating the consensus estimate of $0.51 by $0.01. The firm had revenue of $163.90 million for the quarter, compared to analysts' expectations of $168.23 million. During the same quarter in the previous year, the firm posted $0.35 earnings per share. The company's revenue was up 10.7% on a year-over-year basis. Equities research analysts anticipate that Core Laboratories N.V. will post $2.09 earnings per share for the current fiscal year.

The company declared a dividend that will be paid on Monday the 14th of August 2017. This represents a $2.20 annualized dividend and a yield of 2.37%. The ex-dividend date is Thursday the 13th of July 2017.

ILLEGAL ACTIVITY WARNING: "Sumitomo Mitsui Asset Management Company LTD Maintains Stake in Core Laboratories N.V. (NYSE:CLB)" was originally reported by Week Herald and is the property of of Week Herald. If you are accessing this piece of content on another site, it was stolen and reposted in violation of United States & worldwide trademark and copyright legislation. The legal version of this story can be viewed at https://www.chaffeybreeze.com/2017/08/11/core-laboratories-n-v-nyseclb-shares-bought-by-b-t-capital-management-dba-alpha-capital-management-updated-updated-updated.html.

A number of brokerages have commented on CLB. BidaskClub cut shares of Core Laboratories N.V. from a "hold" rating to a "sell" rating in a research note on Monday, July 31st. ValuEngine raised Core Laboratories N.V. from a "sell" rating to a "hold" rating in a research note on Friday, August 4th. Finally, Scotiabank set a $136.00 price objective on Core Laboratories N.V. and gave the stock a "hold" rating in a research note on Saturday, April 22nd. Zacks Investment Research upgraded Core Laboratories N.V. from a "hold" rating to a "buy" rating and set a $116.00 price objective for the company in a research report on Monday, June 12th. Loop Capital upgraded Core Laboratories N.V. from a "hold" rating to a "buy" rating and increased their price objective for the company from $125.00 to $130.00 in a research report on Friday, April 21st. The company has an average rating of "Hold" and a consensus price target of $117.17.

Core Laboratories N.V. provides reservoir description, production enhancement and reservoir management services to the oil and gas industry.

Core Laboratories N.V. provides reservoir description, production enhancement and reservoir management services to the oil and gas industry. The Company operates through three segments: Reservoir Description, Production Enhancement and Reservoir Management.

Want to see what other hedge funds are holding CLB?

D'autres rapports CampDesrEcrues

Discuter de cet article

SUIVRE NOTRE JOURNAL